Author Archives: Modulight Content

About Modulight Content

Modulight wants to share high-quality scientific publications, white papers, application notes, and other articles. The articles shared are courtesy of the authoring researchers and groups and we're thankful for giving us the permission to honor their work this way. If you have something to share please drop us a line (see the contact form at Contact Us section).

Light-induced cytotoxicity in cells utilizing an automated well plate illuminator

Presented in: SPIE BIOS 2023 Authors: Laura Vesala, Robert Perttilä, Elias Kokko, Johannes Kivelä, Lasse Orsila, Petteri Uusimaa    Presented in: SPIE BIOS 2023 Authors: Laura Vesala, Robert Perttilä, Elias Kokko, Johannes Kivelä, Lasse Orsila, Petteri Uusimaa   Delivering therapeutic drug molecules to the target site and releasing the cargo site-specifically is of major interest in biomedicine. To carry and release drugs to specific target tissues, different nanotechnology approaches have been utilized. These include light-sensitive liposomal carriers, which have been engineered to release cargo from their aqueous cores when illuminated by certain wavelengths of laser light. To study drug release parameters in vitro, Modulight Continue reading →

Photoimmunotherapy for Immunosuppressed Patients and Prevalent and Commonly Known Cancers

Tumors have become more common in recent years across the world. Although immunotherapy is a precise, quick, and efficient way to treat tumors, it generates serious side effects, such as cytokine release syndrome (CRS) and neurotoxicity. Thus, the creation of an efficient and non-harmful immunotherapy approach is urgently required. Photochemical interactions—especially photodynamic therapy (PDT) and photothermal therapy (PTT)—can be used for direct cell killing in treating malignancies. “The leading market participants in the worldwide PIT market include”… “Modulight Corporation”…Tumors have become more common in recent years across the world. Although immunotherapy is a precise, quick, and efficient way to treat tumors, it generates serious side effects, such as cytokine release syndrome (CRS) and neurotoxicity. Thus, the creation of an efficient and non-harmful immunotherapy approach is urgently required. Photochemical interactions—especially photodynamic therapy (PDT) and photothermal therapy (PTT)—can be used for direct cell killing in treating malignancies. "The leading market participants in the worldwide PIT market include"... "Modulight Corporation"... Read article

Modulight Spotlights: LASER-SHARP RESEARCH – February 2023

 Modulight Spotlights: LASER-SHARP RESEARCH – February 2023 The nomination for Laser-Sharp Research goes to Mäki-Mikola et al. at University of Helsinki for their development of a dynamic cell culturing platform for light-activation studies. The developed platform has a flow chamber connected to a peristaltic pump, which creates a flow that resembles the natural fluid flow at the cell surfaces. ML6500 laser was used to release calcein from liposomes to validate the suitability of the platform for light-triggered drug release. Compared to traditional static cell culture Continue reading →

Modulight Geographic Expansion Continues in Europe with Laser 2000

PALO ALTO, CALIFORNIA & TAMPERE, FINLAND, 26TH JANUARY 2023 – Modulight Corp., a biomedical & semiconductor laser manufacturer, is expanding sales in Europe through a distribution partnership with Laser 2000, a pan European solutions provider for lasers and photonics since 1986. The exclusive partnership with Laser 2000 brings Modulight’s products available to customers in Germany, Austria, Switzerland, and France. Laser 2000 customers include several of the biggest technology companies in Europe. The expectation is that this collaboration with Laser 2000 will open significant sales opportunities Continue reading →PALO ALTO, CALIFORNIA & TAMPERE, FINLAND, 26TH JANUARY 2023 – Modulight Corp., a biomedical & semiconductor laser manufacturer, is expanding sales in Europe through a distribution partnership with Laser 2000, a pan European solutions provider for lasers and photonics since 1986. The exclusive partnership with Laser 2000 brings Modulight’s products available to customers in Germany, Austria, Switzerland, and France. Laser 2000 customers include several of the biggest technology companies in Europe. The expectation is that this collaboration with Laser 2000 will open significant sales opportunities Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – December 2022

   Modulight Spotlights: LASER-SHARP RESEARCH – December 2022 This month’s research spotlight goes to H. Wakiyama, H. Kobayashi, et al. at National Cancer Institute, USA. Their study, published in Cancer Immunology Research journal, looked into immunological mechanisms behind hyperprogressive disease. Immune checkpoint inhibitors, despite being a major success story in the field of cancer therapy, unfortunately lead to this rapid progression of cancer in some patients, for yet poorly understood reasons. To study this, the research team partially depleted cytotoxic T cells by photoimmunotherapy, using CD8-targeted Continue reading →

Modulight’s Kalle Palomäki Appointed as Vice Chair of the Enabling Technologies Technical Advisory Committee in QED-C

Modulight’s executive board member, Mr. Kalle Palomäki has been selected as the Vice Chair of the Enabling Technologies Technical Advisory Committee (TAC) in Quantum Economic Development Consortium (QED-C). QED-C is the key organization in the US that has the mission of accelerating the development of the US Quantum market. Celia Merzbacher, QED-C executive director, comments on Mr. Palomäki’s election for the Vice Chair: “Laser technology is especially fundamental in quantum systems, such as trapped ion and neutral atom based qubits, and quantum networking. Lasers truly Continue reading →Modulight’s executive board member, Mr. Kalle Palomäki has been selected as the Vice Chair of the Enabling Technologies Technical Advisory Committee (TAC) in Quantum Economic Development Consortium (QED-C). QED-C is the key organization in the US that has the mission of accelerating the development of the US Quantum market. Celia Merzbacher, QED-C executive director, comments on Mr. Palomäki’s election for the Vice Chair: “Laser technology is especially fundamental in quantum systems, such as trapped ion and neutral atom based qubits, and quantum networking. Lasers truly Continue reading →

Selective depletion of polymorphonuclear myeloid derived suppressor cells in tumor beds with near infrared photoimmunotherapy enhances host immune response

Published in: OncoImmunology Authors: Takuya Kato, Hiroshi Fukushima, Aki Furusawa, Ryuhei Okada, Hiroaki Wakiyama, Hideyuki Furumoto, Shuhei Okuyama, Seiichiro Takao, Peter L. Choyke, Hisataka Kobayashi    Published in: OncoImmunology Authors: Takuya Kato, Hiroshi Fukushima, Aki Furusawa, Ryuhei Okada, Hiroaki Wakiyama, Hideyuki Furumoto, Shuhei Okuyama, Seiichiro Takao, Peter L. Choyke, Hisataka Kobayashi   Myeloid-derived suppressor cells were selectively eliminated within tumors by Ly6G-targeted NIR-PIT, using ML7710 for in vitro and in vivo PIT. Significant tumor growth suppression and survival benefit, as well as abscopal effects, were observed in animal models, showing promise as a cancer immunotherapy.   Read the article here

A Non-Invasive Deep Photoablation Technique to Inhibit DCIS Progression and Induce Antitumor Immunity

Published in: Cancers Authors: Kensuke Kaneko, Hiroshi Nagata, Xiao-Yi Yang, Joshua Ginzel, Zachary Hartman, Jeffrey Everitt, Philip Hughes, Timothy Haystead, Michael Morse, Herbert Kim Lyerly, Takuya Osada    Published in: Cancers Authors: Kensuke Kaneko, Hiroshi Nagata, Xiao-Yi Yang, Joshua Ginzel, Zachary Hartman, Jeffrey Everitt, Philip Hughes, Timothy Haystead, Michael Morse, Herbert Kim Lyerly, Takuya Osada   The study investigated HSP90-targeted PDT for minimally invasive treatment of ductal carcinoma in situ (DCIS), benign breast cancer condition that has potential to progress into breast cancer. PDT with ML8500 combined to ML7710 resulted in effective in vitro cytotoxicity and with ML7710 in vivo, which was further potentiated with PD-L1 immune checkpoint inhibitors.   Read the article Continue reading →